Multicenter observational study of fulvestrant 500 mg in postmenopausal Japanese women with ER positive advanced or recurrent breast cancer after prior endocrine treatment (SBCCSG29 study)

被引：0
|
作者：
Kimizuka, K. [1 ]
Inoue, K. [2 ]
Nagai, S. [2 ]
Saito, T. [3 ]
Nakano, S. [4 ]
Futsuhara, K. [5 ]
Sakurai, T. [6 ]
Yamada, H. [7 ]
Hata, S. [8 ]
Kaneko, S. [9 ]
Kurosumi, M. [10 ]
机构：
[1] Kasukabe Municipal Hosp, Dept Breast Surg, Kasukabe, Japan
[2] Saitama Canc Ctr, Dept Breast Oncol, Saitama, Japan
[3] Saitama Red Cross Hosp, Dept Breast Surg, Saitama, Japan
[4] Kawaguchi Municipal Med Ctr, Dept Surg, Kawaguchi, Japan
[5] Jichi Med Univ, Saitama Med Ctr, Div Breast Oncol, Dept Surg, Saitama, Japan
[6] JCHO Saitama Med Ctr, Dept Surg, Saitama, Japan
[7] Sekishindo Hosp, Dept Surg, Kawagoe, Saitama, Japan
[8] Mitsui Hosp, Dept Breast Surg, Kawagoe, Saitama, Japan
[9] Saitama Cooperat Hosp, Dept Surg, Kawaguchi, Saitama, Japan
[10] Saitama Canc Ctr, Dept Pathol, Saitama, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
57PD
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [31] Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
    Robertson, John F. R.
    Llombart-Cussac, Antonio
    Rolski, Janusz
    Feltl, David
    Dewar, John
    Macpherson, Euan
    Lindemann, Justin
    Ellis, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4530 - 4535
  • [32] Patterns of treatment and outcome with 500-mg fulvestrant in postmenopausal women with hormone receptor-positive/HER2-negative metastatic breast cancer: a real-life multicenter Italian experience
    Palumbo, Raffaella
    Sottotetti, Federico
    Quaquarini, Erica
    Gambaro, Anna
    Ferzi, Antonella
    Tagliaferri, Barbara
    Teragni, Cristina
    Licata, Luca
    Serra, Francesco
    Lapidari, Pietro
    Bernardo, Antonio
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [33] A network meta-analysis of fulvestrant 500 mg versus alternative therapies for second-line treatment of postmenopausal, estrogen receptor-positive advanced breast cancer
    Telford, C.
    Jones, N.
    Batson, S.
    CANCER RESEARCH, 2016, 76
  • [34] Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
    Kuler, I
    Hegg, R.
    Singer, C. F.
    Badwe, R.
    Lowe, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S7 - S7
  • [35] Fulvestrant 500 mg vs 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer
    Kuter, I.
    Hegg, R.
    Singer, C. F.
    Badwe, R.
    Lowe, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 589 - 590
  • [36] A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06)
    Takeuchi, Hideki
    Takei, Hiroyuki
    Futsuhara, Kazushige
    Yoshida, Takashi
    Kojima, Makoto
    Kai, Toshihiro
    Tabei, Toshio
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2014, 19 (01) : 68 - 73
  • [37] Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
    H. Kawaguchi
    N. Masuda
    T. Nakayama
    K. Aogi
    K. Anan
    Y. Ito
    S. Ohtani
    N. Sato
    S. Saji
    E. Tokunaga
    S. Nakamura
    Y. Hasegawa
    M. Hattori
    T. Fujisawa
    S. Morita
    M. Yamaguchi
    T. Yamashita
    Y. Yamamoto
    S. Ohno
    M. Toi
    Breast Cancer Research and Treatment, 2017, 163 : 545 - 554
  • [38] Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)
    Kawaguchi, H.
    Masuda, N.
    Nakayama, T.
    Aogi, K.
    Anan, K.
    Ito, Y.
    Ohtani, S.
    Sato, N.
    Saji, S.
    Tokunaga, E.
    Nakamura, S.
    Hasegawa, Y.
    Hattori, M.
    Fujisawa, T.
    Morita, S.
    Yamaguchi, M.
    Yamashita, T.
    Yamamoto, Y.
    Ohno, S.
    Toi, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 545 - 554
  • [39] A multicenter prospective study to evaluate bone fracture related to adjuvant anastrozole in Japanese postmenopausal women with breast cancer: two-year interim analysis of Saitama Breast Cancer Clinical Study Group (SBCCSG-06)
    Hideki Takeuchi
    Hiroyuki Takei
    Kazushige Futsuhara
    Takashi Yoshida
    Makoto Kojima
    Toshihiro Kai
    Toshio Tabei
    International Journal of Clinical Oncology, 2014, 19 : 68 - 73
  • [40] Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the JBCRG-C06 safari study
    Hagi, Misato
    Kawaguchi, Hidetoshi
    Masuda, Norikazu
    Saji, Shigehira
    Yamamoto, Yutaka
    Nakayama, Takahiro
    Aogi, Kenjiro
    Anan, Keisei
    Ito, Yoshinori
    Ohtani, Shoichiro
    Sato, Nobuaki
    Takano, Toshimi
    Tokunaga, Eriko
    Nakamura, Seigo
    Hasegawa, Yoshie
    Hattori, Masaya
    Fujisawa, Tomomi
    Yamaguchi, Miki
    Yamashita, Hiroko
    Yamashita, Toshinari
    Yotsumoto, Daisuke
    Morita, Satoshi
    Toi, Masakazu
    Ohno, Shinji
    CANCER RESEARCH, 2020, 80 (04)
12345